UnknownNot Applicable

The Cardio-Oncology Breast Cancer Study

Sweden320 participantsStarted 2014-07

Plain-language summary

The main objective of this randomized controlled trial is to test the association between standard cardiac risk factors, biomarkers and parameters of echocardiography, electrocardiography, and cardiac magnetic resonance imaging, (predictors) and subsequent occurrence, frequency and severity of clinical or subclinical cardiotoxicity (outcome) within and between-groups, before start of chemotherapy, during treatment and at 1, 5, and 10 years after the completion of the chemotherapy among women with early breast cancer.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women with newly diagnosed breast cancer who are eligible to receive neo-adjuvant or adjuvant chemotherapy, with or without trastuzumab, according to the guidelines for breast cancer. * Written informed consent must be given. Exclusion Criteria: * A history of heart disease; ischemic heart disease, arrhythmias, heart failure, and valve diseases. * Previously received oncological treatment for any malignancy. * Other disease or conditions that complicates or precludes the patient from following the study protocol.

What they're measuring

Event free survival

Timeframe: 1 year after the completion of the chemotherapy.

Trial details

NCT IDNCT02571894

SponsorKarolinska University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-02

View on ClinicalTrials.gov More Cardiotoxicity trials